We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App




Clinical Microarray System Developed for Genetic Analysis Screening

By LabMedica International staff writers
Posted on 02 Jan 2023

In precision medicine, preoperative or postoperative genetic testing can be used to stratify patients according to disease states and select appropriate drugs, enabling efficient delivery of personalized treatment. More...

Postoperative monitoring can also be used to predict the possibility of recurrence and other prognostic factors. With the advancement of liquid biopsy genetic testing, preventive medicine is expected to have an impact in the future in terms of estimating the risk of morbidity and preventing diseases.

Clinical Scientists at the Yamaguchi University Graduate School of Medicine (Ube, Japan) and their colleagues at Toyo Kohan Co., Ltd (Shinagawa, Tokyo, Japan) developed a novel microarray-based genetic analysis system that uses a Peltier element to overcome the issues of conventional microarrays, such as the long measurement time and high cost. They constructed a microarray system to detect the UDP-glucuronosyltransferase gene polymorphisms UGT1A1*6 and UGT1A1*28 in patients eligible for irinotecan hydrochloride treatment for use in clinical laboratories. Irinotecan hydrochloride is used to treat cancer.

Threshold values were set based on the mean and standard deviation of genotype determination values for each genotype calculated from 22 human specimens. Then, genotype determination values were calculated using the developed genetic analyzer for 111 human specimens that had already been examined using the existing Invader UGT1A1 Molecular Assay (Sekisui Medical, Tokyo, Japan), and the genotypes were determined based on the genotype determination thresholds that were set. Amplification was performed on a Mastercycler Pro S PCR system (Eppendorf, Hamburg, Germany).

The investigators reported that the hybridization temperature reached its target in 1/27th of the time required by the conventional system. They assessed 111 human clinical samples and found that their results agreed with those obtained using existing methods. The total time for the newly developed device was reduced by 85 minutes compared to that for existing methods, as the automated DNA microarray eliminates the time that existing methods spend on manual operation.

The authors concluded that a microarray system suitable for clinical use was developed using a surface treatment that enables high-density and strong DNA fixation. Using the assay system for the UGT1A1*28 and UGT1A1*6 polymorphisms, the optimal hybridization temperature and thresholds for genotype determination were set. In a performance evaluation using 111 samples, the results of the present device were comparable to those of an existing assay. Therefore, they proposed that the system developed in their study is suitable for genetic testing in clinical laboratories. The study was published on December 26, 2022 in the journal Practical Laboratory Medicine.

Related Links:
Yamaguchi University Graduate School of Medicine
Toyo Kohan Co., Ltd
Sekisui Medical 
Eppendorf 


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Toxoplasma Gondii Test
Toxo IgG ELISA
New
Vasculitis Diagnostic Test
AESKULISA Vasculitis-Screen
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.